MichaelM.WangMD

Hematology • Houston, TX

Hematologic Oncology

Physician

Join to view full profile

Dr. Wang is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Wang's full profile

Already have an account?

Office
1515 Holcombe Blvd
Houston, TX 77030

Education & Training

University of Texas Health Science Center at HoustonFellowship, Hematology and Medical Oncology, 1999 - 2002
Norwalk Hospital/Yale UniversityResidency, Internal Medicine, 1995 - 1998
University of MichiganInternship, Internal Medicine, 1994 - 1995
Shandong Medical UniversityClass of 1985
Shandong Medical UniversityClass of 1985

Certifications & Licensure

FL State Medical License 2021 - Present
TN State Medical License 2022 - 2026
AL State Medical License 2022 - 2025
AZ State Medical License 2022 - 2025
GA State Medical License 2022 - 2025
LA State Medical License 2022 - 2025
MS State Medical License 2022 - 2025
OK State Medical License 2020 - 2025
TX State Medical License 1998 - 2025
WA State Medical License 2022 - 2025
CT State Medical License 1997 - 1998
American Board of Internal Medicine Medical Oncology
Join now to see all

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014

Clinical Trials

Postoperative Radiotherapy for Patients With IIIA (N2) Non-small Cell Lung Cancer Start of enrollment: 2009 Feb 18
Completed
Phase 3
Cisplatin/Etoposide and Concurrent Radiotherapy With or Without Celecoxib in Patients With Unresectable Locally Advanced Non-small Cell Lung Cancer (NSCLC) Start of enrollment: 2011 Dec 01
Unknown status
Phase 2
Ibrutinib and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Older Patients With Newly Diagnosed Mantle Cell Lymphoma Start of enrollment: 2013 Jul 15
Active, not recruiting
Phase 2
Comparable Study of Different Thoracic Radiotherapy Regimens for Extensive Stage Small Cell Lung Cancer Start of enrollment: 2017 Dec 01
Recruiting
Not Applicable
Ibrutinib, Rituximab, Venetoclax, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma Start of enrollment: 2019 May 01
Active, not recruiting
Phase 2
Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell Lymphoma Start of enrollment: 2020 Aug 07
Recruiting
Phase 2
Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma Start of enrollment: 2021 Jun 30
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

1 citations
Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy.
Rishika Prasad, Abdur Rehman, Lubna Rehman, Faezeh Darbaniyan, Viktoria Blumenberg
Blood. 2025-02-20
High-risk MCL: recognition and treatment.
Preetesh Jain, Michael Wang
Blood. 2025-02-13
1 citations
Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
Michael Wang, Wojciech Jurczak, Marek Trneny, David Belada, Tomasz Wrobel
The Lancet. Oncology. 2025-02-01

Press Mentions

$FDA Approves Denileukin Diftitox-cxdl for Relapsed/Refractory Cutaneous T-Cell Lymphoma$
FDA Approves Denileukin Diftitox-cxdl for Relapsed/Refractory Cutaneous T-Cell LymphomaAugust 12th, 2024
Acalabrutinib and Chemotherapy Enhance Survival in Mantle Cell LymphomaJune 23rd, 2024
FDA Approves CAR-T Therapy in Mantle Cell LymphomaMay 31st, 2024
Join now to see all